Oslo University Hospital is a university hospital in Oslo, Norway. With over 24,000 employees it is the largest hospital organization in Europe. It is affiliated with the Faculty of Medicine of the University of Oslo and is one of the largest medical research institutions in Europe.

There are 1,870 beds in Oslo University Hospital, Dept of paediatric haemato- and oncology.

During the past decade, Oslo University Hospital, Dept of paediatric haemato- and oncology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oslo University Hospital, Dept of paediatric haemato- and oncology" #1 collaborator was "NordForsk" with 2 trials as a collaborator, "The Swedish Childhood Cancer Foundation" with 2 trials as a collaborator, "Aamu Pediatric Cancer Foundation" with 1 trials as a collaborator, "Acreditar - Associação de Pais e Amigos das Crianças com Cancro" with 1 trials as a collaborator and "Amgen" with 1 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "Oslo University Hospital, Dept of paediatric haemato- and oncology" are "Leukemia, Acute Lymphoblastic" (2 trials). Many other conditions were trialed in "Oslo University Hospital, Dept of paediatric haemato- and oncology" in a lesser frequency.

Most popular intervention types in "Oslo University Hospital, Dept of paediatric haemato- and oncology" are "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "6-tioguanine+Standard Maintenance Therapy" (1 trials), "Blinatumomab" (1 trials), "Imatinib" (1 trials), "Inotuzumab Ozogamicin+Standard Maintenance Therapy" (1 trials) and "Observational" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oslo University Hospital, Dept of paediatric haemato- and oncology" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Oslo University Hospital, Dept of paediatric haemato- and oncology". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Oslo University Hospital, Dept of paediatric haemato- and oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Oslo University Hospital, Dept of paediatric haemato- and oncology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".